Scientists at Rutgers and other universities build technology that could lead to rapid discovery of new medicines and biomarkers hidden in genomes
Discovering the function of a gene requires cloning a DNA sequence and expressing it. Until now, this was performed on a one-gene-at-a-time basis, causing a bottleneck. Scientists at Rutgers University-New Brunswick in collaboration with Johns Hopkins University and Harvard Medical School have invented a technology to clone thousands of genes simultaneously and create massive libraries of proteins from DNA samples, potentially ushering in a new era of functional genomics.
“We think that the rapid, affordable, and high-throughput cloning of proteins and other genetic elements will greatly accelerate biological research to discover functions of molecules encoded by genomes and match the pace at which new genome sequencing data is coming out,” said Biju Parekkadan, an associate professor in the Department of Biomedical Engineering at Rutgers University-New Brunswick.
In a study published online today in the journal Nature Biomedical Engineering, the researchers showed that their technology – LASSO (long-adapter single-strand oligonucleotide) probes – can capture and clone thousands of long DNA fragments at once.
As a proof-of-concept, the researchers cloned more than 3,000 DNA fragments from E. coli bacteria, commonly used as a model organism with a catalogued genome sequence available.
“We captured about 95 percent of the gene targets we set out to capture, many of which were very large in DNA length, which has been challenging in the past,” Parekkadan said. “I think there will certainly be more improvements over time.”
They can now take a genome sequence (or many of them) and make a protein library for screening with unprecedented speed, cost-effectiveness and precision, allowing rapid discovery of potentially beneficial biomolecules from a genome.
In conducting their research, they coincidentally solved a longstanding problem in the genome sequencing field. When it comes to genetic sequencing of individual genomes, today’s gold standard is to sequence small pieces of DNA one by one and overlay them to map out the full genome code. But short reads can be hard to interpret during the overlaying process and there hasn’t been a way to sequence long fragments of DNA in a targeted and more efficient way. LASSO probes can do just this, capturing DNA targets of more than 1,000 base pairs in length where the current format captures about 100 base pairs.
The team also reported the capture and cloning of the first protein library, or suite of proteins, from a human microbiome sample. Shedding light on the human microbiome at a molecular level is a first step toward improving precision medicine efforts that affect the microbial communities that colonize our gut, skin and lungs, Parekkadan added. Precision medicine requires a deep and functional understanding, at a molecular level, of the drivers of healthy and disease-forming microbiota.
Today, the pharmaceutical industry screens synthetic chemical libraries of thousands of molecules to find one that may have a medicinal effect, said Parekkadan, who joined Rutgers’ School of Engineering in January.
“Our vision is to apply the same approach but rapidly screen non-synthetic, biological or ‘natural’ molecules cloned from human or other genomes, including those of plants, animals and microbes,” he said. “This could transform pharmaceutical drug discovery into biopharmaceutical drug discovery with much more effort.”
The next phase, which is underway, is to improve the cloning process, build libraries and discover therapeutic proteins found in our genomes, Parekkadan said.
The Latest on: Precision medicine
Precision Medicine Group acquires scientific and medical communications company, ETHOS
on July 11, 2018 at 11:30 pm
Precision Medicine Group, Inc., announced it is acquiring ETHOS Health Communications, a Pennsylvania-based agency specializing in the interpretation and communication of innovative medical science. T... […]
KLAS: 13 precision medicine vendors with high 'mindshare' among providers
on July 11, 2018 at 3:47 pm
In June, KLAS Research released the first of its two-part report on precision medicine vendors. For the report, the health IT research firm conducted interviews and research to select 13 precision med... […]
Cancer, Redefined: Personalized Medicine
on July 11, 2018 at 10:37 am
Personalized medicine (also termed “precision medicine”) is the tailoring of medical treatment to the individual characteristics of each patient. Traditionally, cancer treatment progressed along the p... […]
New research explores oncologists' views on precision medicine
on July 11, 2018 at 8:48 am
Precision medicine has the potential to transform cancer care, but challenges need to be addressed. Here’s what more than 160 oncologists nationwide said about their aspirations and hesitations for th... […]
St. Elizabeth launches precision medicine center focused on genetics
on July 10, 2018 at 11:54 am
St. Elizabeth Healthcare has launched a precision medicine program, which will rely on genetic testing to improve care for cancer patients and others. The genetic makeup of patients will be examined t... […]
Gradual Progress In Precision Non-Oncology, But Challenges Persist
on July 10, 2018 at 7:44 am
Of 132 new molecular entities and biologics identified as approved precision medicines by the Personalized Medicine Coalition (PMC) in their 2017 report, an impressive number, 85, are non-oncology pro... […]
Sonic Healthcare Selects Translational Software’s Pharmacogenomics Platform to Advance Precision Medicine in Australia
on July 10, 2018 at 6:00 am
Translational Software®, Inc. (TSI), a global leader in the intelligent use of genetic data for clinical decision support, has finalized an agreement with Sonic Genetics, a member of Sonic Healthcare, ... […]
Precision Medicine Developer Illumina Best in Class. Buy on Pullbacks
on July 10, 2018 at 3:04 am
Illumina (ILMN) shares have performed well, rising 25.6% in 2018, and 58.2% over the last year. Although the trailing price-to-earnings ratio is 71x, sales growth remains very strong at 14.7%. Buy Ill... […]
Landmark Study Shows Precision Medicine Benefits Pancreatic Cancer Patients
on July 6, 2018 at 1:49 pm
Pancreatic Cancer Action Network, Perthera, Inc., Published Study Finds Patients with "Actionable" Mutations Who Received Targeted Therapies Have Significantly Improved Outcomes "There has been a long... […]
Precision Medicine Market to Record Sturdy Growth by 2024
on July 5, 2018 at 2:30 pm
Precision medicine is an upcoming disease treatment approach which is devised based on individual variability in genes, environment, and lifestyle for each person. Often the term is used interchangeab... […]
via Google News and Bing News